VBWG
Monograph

Data and Commentary:The HOPE Study

• Effects of angiotensin-converting enzyme inhibition on cardiovascular events in high-risk patients


The Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med. 2000; 342:145-153.


With Commentary by
Carl J. Pepine, MD
University of Florida College of Medicine

This discourse is offered as a continuing medical education program from the University of Florida College of Medicine.

The Heart Outcomes Prevention Evaluation (HOPE) Study was a landmark clinical evaluation of tissue angiotensin-converting enzyme inhibition. Because of the potential clinical implications, the main findings from this trial were released by the New England Journal of Medicine prior to publication. This final report has now been published, and we are pleased to include a reprint and accompanying commentary.

The success of the HOPE Study can be understood in the context of endothelial dysfunction present in patients with readily identifiable risk factors of elevated lipids, hypertension, and diabetes mellitus. All of these risk factors can contribute to the development and progression of atherosclerosis and its unwanted sequelae of myocardioal ischemia, infarction, heart failure, and death. Indeed, one of the postulated mechanisms of the beneficial effects of HOPE may be the improvement in endothelial function seen in earlier trials.

This CME program is part of a series of educational programs aimed at taking the mystery out of vascular biology and making it relevant to patient care.






angiotensincardiovascularenzymeEvaluationinhibitionInvestigatorsPrevention

Related at vwbg.org

HOPE: New validation for the importance of tissue ACE inhibition

The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensin-converting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events.

HOPE-TOO: Extended use of ACEI reduces CV risk and new diabetes, independent of baseline risk

Results from large clinical trials provide evidence that angiotensin-converting enzyme inhibitors (ACEIs) are effective in the treatment of cardiovascular (CV) disease.

Core Curriculum

The Renin-Angiotensin-Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction

View/Download individual slides (93 Slides)
More related